atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.
Ticker:
atai
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
PCN-101
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided